ArticleAmerican journal of preventive medicine2025
Clinician Prescribing Practices Involving Medications for Alcohol Use Disorder.
Article in American journal of preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Discontinuation of medications for alcohol use disorder in the United States: Patient, prescriber and medication predictors.Addiction (Abingdon, England) · 2026Observational
- Clinician-Level Variation in MAUD Prescribing: The Role of Behavioral Health Experience.The journal of behavioral health services & research · 2026Article
- Alcohol use disorder-associated pain: clinical and preclinical evidence.Alcohol (Fayetteville, N.Y.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionDespite the heavy toll of alcohol use disorder (AUD) in the U.S., efficacious medications for AUD (MAUD) are rarely used. Minimal research has explored clinician prescribing practices involving MAUD.
methodsUsing a large national database of electronic health records, this cross-sectional analysis, conducted in 2023-2024, identified clinicians with at least 1 prescription order for an FDA-approved MAUD (naltrexone, acamprosate, or disulfiram) for a patient with AUD during 2016-2021. Descriptive statistics captured clinician-level prescribing volume and type of medication prescribed. Logistic regression models estimated the association between clinician characteristics and number of MAUD patients and type of medications prescribed.
resultsAmong the 38,626 clinician-years identified in the EHR data (representing 19,840 unique clinicians), 59% prescribed MAUD to a single patient. Psychiatrists (AOR=4.4, 95% CI=3.8, 4.9) and advanced practice providers (AOR=1.8, 95% CI=1.6, 2.0) were significantly more likely than primary care physicians to prescribe MAUD to 4 or more patients. Clinicians in the top tertile in the percentage of patients with a substance use disorder diagnosis were also more likely to prescribe MAUD to more patients (AOR=8.1, 95% CI=7.1, 9.7). These same clinician characteristics were also associated with greater odds of prescribing more than 1 type of AUD medication.
conclusionsMost clinicians prescribing MAUD in a year did so rarely. Policy and health system change is needed to improve clinicians' pharmacologic treatment of AUD, with a focus on primary care physicians, with whom individuals with AUD may have the most frequent contact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.